相关实验视频
Updated: Jun 12, 2026

07:07
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
12.6K
对补偿性环素D2反应的能力使得Trametinib在犬类粘膜黑色素瘤中具有抗性
Bih-Rong Wei1,2, Vincenzo Verdi1, Shuling Zhang1
1Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Cancers
|July 29, 2025
概括
粘膜黑色素瘤 (MM) 细胞通过从cyclin D1切换到cyclin D2.2,对Trametinib等MEK抑制剂产生抗性. 抑制性环林D2促进了生存和繁殖,导致治疗耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 比较医学是一种比较医学.
背景情况:
- 粘膜黑色素瘤 (MM) 是一种具有攻击性的癌症,治疗选择有限,治疗耐药性频繁.
- 由于共享的特征,犬类MM作为人类MM的有价值模型.
- 了解耐药机制对于改善MM治疗结果至关重要.
研究的目的:
- 调查D型环林在介导狗MM中对MEK抑制的耐药性的作用.
- 探索治疗耐药性的Ras/MAPK和PI3K/AKT/mTOR信号通路之间的交叉声.
- 评估环林D2调节对MM细胞增殖和生存的影响.
主要方法:
- 对五种具有不同药物敏感性的犬类MM细胞系进行特拉美丁尼布治疗.
- 信号通路激活,细胞周期进展,增殖和亡的分析.
- 通过siRNA淘汰和诱导性过度表达来操纵cyclin D2表达.
主要成果:
- 特拉美替尼布在所有MM细胞系中降低了环林D1的表达.
- 耐药的MM细胞上调了环素D2,促进了增殖和生存.
- 在耐药细胞中抑制环林D2恢复了对特拉美丁尼布的敏感性.
- 在敏感细胞中过度表达环素D2提高了生存率.
结论:
- 从环素D1到环素D2表达的补偿性转移是MM对MEK抑制剂耐药性的关键机制.
- 向环素D2可能是克服粘膜黑色素瘤耐药性的治疗策略.
相关概念视频
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

